分子医药农业研究进展

分子医药农业是利用转基因植物为载体,以农业生产的方式规模化生产各种有治疗用途的重组蛋白质及多肽。近20年来,随着植物生物反应器技术的多元化发展以及日趋成熟,植物分子医药农业产业悄然而生。近几年,一些分子医药农业生产的植物源医药产品已实现规模化生产,并进入市场。文中结合国内外最新的研究进展,重点对几种主要植物生物反应器的研究、产品的规模化生产以及产业化进程进行了阐述,以期为我国分子医药农业领域的研究与应用提供参考。     

植物生物反应器优化策略与最新应用*

随着分子生物学和植物基因工程的迅猛发展以及分子医药和现代农业等学科的交叉融合,植物生物反应器已成为分子医药农业的核心内容。利用植物生物反应器生产抗体、疫苗和功能性食品,具有规模化、成本低、安全性高、周期短等优势。2022年2月,加拿大卫生部批准了新型冠状病毒疫苗Covifenz^®,这是世界首款植物源人体疫苗,标志着以植物生物反应器为代表的分子医药农业时代的来临。综述植物叶片和种子等代表性的植物生物反应器类型,分析瞬时表达系统和稳定表达系统的构建原理和应用,探讨通过启动子和密码子优化、糖基化过程“人源化”、基因沉默抑制和蛋白酶作用抑制等优化植物生物反应器的策略,总结国内外抗体、疫苗和功能性食品等植物源产品的开发进展,以期为我国植物生物反应器的研究及其在分子医药领域的应用提供参考。     

植物生物反应器在分子医药农业中的应用

植物生物反应器作为分子医药农业的核心内容,与动物反应器和微生物反应器相比具有操作简便、成本低、规模化、周期短等优势,越来越多地被人们认识和应用。阐述了植物生物反应器转化载体构建和基因优化的方法、常用的植物受体种类,以及植物表达系统类型三个方面的研究进展。随着药用蛋白需求量的大幅度增加,植物生物反应器以其低成本的优势将显示出广阔的应用前景。     

高价值的医药分子农业

植物转基因技术使传统农业逐渐向分子农业转型。农业的作用由原来的简单的提供衣、食、住扩展到为医药业、工业提供优质、低廉的原料或产品。医药分子农业作为分子农业的重要组成部分,已改变了传统农业的生产结构,并因其自身具有较高的经济价值而将给农业带来巨大的经济效益。     

植物生物反应器研究进展

植物生物反应器是近年来生物技术领域新的研究方向,利用农作物进行疫苗、药用蛋白的生产,具有广阔的市场前景和商业价值。研究证明,用各种农作物为载体的植物生物反应器产品可通过种子、果实或块茎表达,便于贮藏、运输和利用。它拓宽了传统农业概念,成为现代生物农业重要的研究方向之一,推动了生物经济快速健康的前进,促进农业可持续发展。综述植物生物反应器的研究与应用现状,并对转基因作物作为植物生物反应器的发展前景作分析和展望。     

植物生物反应器表达药用蛋白研究新进展

植物生物反应器被称为"分子农田",它具有无限生产重组蛋白的巨大潜力。利用转基因植物表达的重组蛋白具备原有的理化性质和生物活性,从而为人类提供了一种大量生产药用蛋白的安全可靠、经济、方便的新生产体系。目前已广泛运用于工业、农业尤其是生命科学以及医学制造领域。用植物生物反应器产重组疫苗、重组抗体和其他药用蛋白已成为国内外基因工程研究热点之一。然而,转基因植物产物的表达量、下游加工等问题却也成为利用植物生物反应器应用的限制因素。本文就其优势、近三年内国内外转基因植物生产药用蛋白的研究进展、存在问题及对策作一综述。     

植物生物反应器研究现状、瓶颈及策略

近10年,植物作为重组蛋白生产系统是生命科学中研究最活跃领域之一。植物系统具有低成本、安全和易规模化优势,其表达生物活性药用蛋白能力已被许多研究所证实;同时,植物药用蛋白产品还表现出潜在的市场和广阔应用前景。鉴于此,回顾了植物生物反应器兴起,介绍了植物表达系统和重组蛋白研究现状,综述了植物生物反应器面临瓶颈问题、解决对策和未来一段时间内研究热点;在展望植物生物反应器前景同时,对我国研究现状、与国外差距和未来发展应采取策略进行了讨论。     

植物医药基因工程研究进展

从抗体及动物疫苗在转基因植物中的表达,阐述了植物医药基因工程的进展及意义.植物抗体的表达,在研究植物的代谢和发育、抗病植株的获取以及规模化生产抗体等方面有着广泛的用途.动物疫苗在植物中的表达,简化了疫苗的生产过程,并能使人体获得持久性的疾病防御能力.     

植物细胞培养生物反应器的种类特点及展望

生物反应器技术应用于植物细胞培养既可以打破环境条件的限制,又有助于生产过程的人为调控,为植物细胞大规模培养或工厂化直接生产植物细胞有用代谢产物创造了条件,是当前植物细胞培养工作的研究热点。在介绍植物细胞培养特点的基础上,对适用于植物细胞培养的各类生物反应器(搅拌式生物反应器、非搅拌式生物反应器、用于植物细胞固定化培养的生物反应器、光生物反应器以及一次性培养生物反应器)的原理、优缺点等进行比较分析,最后提出了植物细胞培养生物反应器研究的发展方向,以期为植物细胞培养生物反应器的选择及改良提供参考。     

植物生物反应器在生物制药方面应用的进展

植物生物反应器表达产物贮藏在种子、果实、块茎中便于贮运,并具有无毒性和副作用,安全可靠,无残存DNA和潜在致病致癌性等优点,鉴于以上优点,所以,基于转基因植物的"分子农业"在上世纪末刚提出就成为研究热点。目前,在生物药用蛋白成为世界研究潮流的大背景下,关于植物生物反应器的研究业已取得一定突破和成绩。本文就在生物制药方面植物生物反应器的应用进展进行综述。     

The emerging role of mass spectrometry-based proteomics in molecular pharming practices

Molecular pharming relies on the integration of foreign genes into a plant system for production of the desired recombinant protein. The speed, scalability, and lack of contaminating human pathogens highlights plants as an enticing and feasible system to produce diverse protein-based products, including vaccines, antibodies, and enzymes. However, limitations of expression levels, host defense responses, and production irregularities underscore distinct areas for improvement within the molecular pharming pipeline. Within the past five years, mass spectrometry-based proteomics has begun to address these critical areas and show promise in advancing our understanding of the complex biological systems driving molecular pharming. Further, opportunities to leverage comprehensive proteome profiling have surfaced to meet good manufacturing practice regulations and move biopharmaceuticals derived from plants into mainstream production.     

Transgenic rice endosperm as a bioreactor for molecular pharming

Plants provide a promising expression platform for producing recombinant proteins with several advantages in terms of high expression level, lower production cost, scalability, and safety and environment-friendly. Molecular pharming has been recognized as an emerging industry with strategic importance that could play an important role in economic development and healthcare in China. Here, this review represents the significant advances using transgenic rice endosperm as bioreactor to produce various therapeutic recombinant proteins in transgenic rice endosperm and large-scale production of OsrHSA, and discusses the challenges to develop molecular pharming as an emerging industry with strategic importance in China.     

Recombinant plant-derived pharmaceutical proteins: current technical and economic bottlenecks

Molecular pharming is a cost-effective platform for the production of recombinant proteins in plants. Although the biopharmaceutical industry still relies on a small number of standardized fermentation-based technologies for the production of recombinant proteins there is now a greater awareness of the advantages of molecular pharming particularly in niche markets. Here we discuss some of the technical, economic and regulatory barriers that constrain the clinical development and commercialization of plant-derived pharmaceutical proteins. We also discuss strategies to increase productivity and product quality/homogeneity. The advantages of whole plants should be welcomed by the industry because this will help to reduce the cost of goods and therefore expand the biopharmaceutical market into untapped sectors.     

Molecular pharming in cereal crops

There are many different agricultural expression systems that can be used for the large-scale production of recombinant proteins, but field-grown cereal crops are among the most attractive because recombinant proteins can be targeted to accumulate in the seed, and specifically in the endosperm, which has evolved naturally as a protein storage tissue. Within the developing endosperm, proteins are supplied with molecular chaperones and disulfide isomerases to facilitate folding and assembly, while the mature tissue is desiccated to prevent proteolytic degradation. Proteins expressed in cereal seeds can therefore remain stable for years in ambient conditions. Recent basic research has revealed a surprising diversity of protein targeting mechanisms in the endosperm, which can help to control post-translational modification and accumulation. Applied research and commercial development has seen several pharmaceutical proteins produced in cereals reach late stage preclinical development and the first clinical trials, with a number of companies now dedicated to developing cereal-based production platforms. In this review we discuss the basic science of molecular pharming in cereals, some of the lead product candidates, and challenges that remain to be addressed including the emerging regulatory framework for plant-made pharmaceuticals.     

Plant plastid engineering

Genetic material in plants is distributed into nucleus, plastids and mitochondria. Plastid has a central role of carrying out photosynthesis in plant cells. Plastid transformation is becoming more popular and an alternative to nuclear gene transformation because of various advantages like high protein levels, the feasibility of expressing multiple proteins from polycistronic mRNAs, and gene containment through the lack of pollen transmission. Recently, much progress in plastid engineering has been made. In addition to model plant tobacco, many transplastomic crop plants have been generated which possess higher resistance to biotic and abiotic stresses and molecular pharming. In this mini review, we will discuss the features of the plastid DNA and advantages of plastid transformation. We will also present some examples of transplastomic plants developed so far through plastid engineering, and the various applications of plastid transformation.     

Animal pharming,two decades on

Since its inception 20 years ago, the animal pharming industry has promoted transgenic animals as a cost-effective method of biopharmaceutical production. However, it took until 2006 for the first therapeutic product to gain regulatory approval. This was an important milestone, but scepticism still abounds. Can pharming regain investor confidence, and will society accept transgenic livestock as a production method? There is some cause for optimism, biopharmaceuticals are a large, expanding market and animal pharming has already made considerable strides. A novel production platform has been established, groundbreaking technologies developed, a necessary regulatory framework put in place. Nevertheless, despite cost advantages, pharming has become a niche production method and its long term success may depend on products unique to transgenic animals.